Evidence map›Paper›PMID 30858103›Full record

ArticleNeuropharmacology2019

A novel dopamine D1 receptor agonist excites delay-dependent working memory-related neuronal firing in primate dorsolateral prefrontal cortex.

Min Wang, Dibyadeep Datta, John Enwright, Veronica Galvin, Sheng-Tao Yang, Constantinos Paspalas, Rouba Kozak, David L Gray, David A Lewis, Amy F T Arnsten

Open access · hybridAbstract read
In one paragraph

Article in Neuropharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 53 citations in OpenAlex.

  1. The Signaling and Pharmacology of the Dopamine D1 Receptor.Frontiers in cellular neuroscience · 2021
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Dopamine DNeuroscience · 2024
    Article
  6. Review
  7. Dynamic Network Connectivity: from monkeys to humans.Frontiers in human neuroscience · 2024
    Review
  8. Article
  9. Article
  10. Pharmacological reviews · 2023
    Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. A Dopamine DThe Journal of pharmacology and experimental therapeutics · 2022
    Article
  20. Dopamine DThe international journal of biochemistry & cell biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Min WangDepartment of Neuroscience, Yale University School of Medicine, New Haven, CT, 06510, USA. Electronic address: min.wang@yale.edu.
Dibyadeep DattaDepartment of Neuroscience, Yale University School of Medicine, New Haven, CT, 06510, USA; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.
John EnwrightDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.
Veronica GalvinDepartment of Neuroscience, Yale University School of Medicine, New Haven, CT, 06510, USA.
Sheng-Tao YangDepartment of Neuroscience, Yale University School of Medicine, New Haven, CT, 06510, USA.
Constantinos PaspalasDepartment of Neuroscience, Yale University School of Medicine, New Haven, CT, 06510, USA.
Rouba KozakPfizer Inc, Internal Medicine Unit, Pfizer Inc., 1 Portland St., Cambridge, MA, 02139, USA.
David L GrayPfizer Inc, Internal Medicine Unit, Pfizer Inc., 1 Portland St., Cambridge, MA, 02139, USA.
David A LewisDepartment of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.
Amy F T ArnstenDepartment of Neuroscience, Yale University School of Medicine, New Haven, CT, 06510, USA. Electronic address: amy.arnsten@yale.edu.
Yale University · USPfizer (United States) · USUniversity of Pittsburgh · US

Funding

Statistics and Data Management CoreP50MH103204 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SIBILLE, ETIENNE L · 2014 to 2018
$10.8M
SCHIZOPHRENIA AND CORTICAL DOPAMINE/GABA INTERACTIONSR01MH043784 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEWIS, DAVID A · 1988 to 2023
$7.2M
GABA Neurons and Cortical Circuitry in SchizophreniaR37MH043784 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LEWIS, DAVID A · 2001 to 2010
$6.8M
NEUROBIOLOGY OF CORTICAL SYSTEMST32NS007224 · NINDS · YALE UNIVERSITY · PI CARDIN, JESSICA A · 1985 to 2025
$4.6M
Highly evolved brain circuits in primates: molecular vulnerabilities for diseaseDP1AG047744 · NIA · YALE UNIVERSITY · PI ARNSTEN, AMY F.T. · 2013 to 2017
$4.1M
NIA NIH HHS DP1 AG047744NIMH NIH HHS P50 MH103204NIMH NIH HHS R01 MH043784NIMH NIH HHS R37 MH043784NINDS NIH HHS T32 NS007224
6 · The paper itself

Abstract

Decades of research have emphasized the importance of dopamine (DA) D1 receptor (D1R) mechanisms to dorsolateral prefrontal cortex (dlPFC) working memory function, and the hope that D1R agonists could be used to treat cognitive disorders. However, existing D1R agonists all have had high affinity for D1R, and engage β-arrestin signaling, and these agonists have suppressed task-related neuronal firing. The current study provides the first physiological characterization of a novel D1R agonist, PF-3628, with low affinity for D1R -more similar to endogenous DA actions- as well as little engagement of β-arrestin signaling. PF-3628 was applied by iontophoresis directly onto dlPFC neurons in aged rhesus monkeys performing a delay-dependent working memory task. Aged monkeys have naturally-occurring loss of DA, and naturally-occurring reductions in dlPFC neuronal firing and working memory performance. We found the first evidence of excitatory actions of a D1R agonist on dlPFC task-related firing, and this PF-3628 beneficial response was blocked by co-application of a D1R antagonist. These D1R actions likely occur on pyramidal cells, based on previous immunoelectron microscopic studies showing expression of D1R on layer III spines, and current microarray experiments showing that D1R are four times more prevalent in pyramidal cells than in parvalbumin-containing interneurons laser-captured from layer III of the human dlPFC. These results encourage the translation of D1R mechanisms from monkey to human, with the hope PF-3628 and related, novel D1R agonists will be more appropriate for enhancing dlPFC cognitive functions in patients with mental disorders.

Indexed as

AnimalsCatecholsDopamine AgonistsFemaleMacaca mulattaMaleMemory, Short-TermNeuronsPrefrontal CortexReceptors, Dopamine D1CatecholsDopamine AgonistsReceptors, Dopamine D1AgingCognitionGABA interneuronPyramidal cellSchizophrenia

Identifiers

PMID30858103
PMCPMC6475613
OpenAlexW2922121074

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.